{
  "id": 9523,
  "url": "https://doi.org/10.1016/s2468-1253(24)00034-7",
  "title": "A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial",
  "summary": "BACKGROUND: Management strategies and clinical outcomes vary substantially in patients newly diagnosed with Crohn's disease. We evaluated the use of a putative prognostic biomarker to guide therapy by assessing outcomes in patients randomised to either top-down (ie, early combined immunosuppression with infliximab and immunomodulator) or accelerated step-up (conventional) treatment strategies. METHODS: PROFILE (PRedicting Outcomes For Crohn's disease using a moLecular biomarker) was a multicentr",
  "authors": "Nurulamin M Noor, James Lee, Simon Bond, Francis Dowling, Biljana Brezina, Kamal Patel",
  "category": "research",
  "topics": "healthcare",
  "orgs": null,
  "regions": null,
  "published_at": "2024-02-22T00:00:00.000Z",
  "fetched_at": "2026-07-14T16:33:57.576Z",
  "source_slug": "openalex",
  "source_name": "OpenAlex",
  "source_homepage": "https://openalex.org",
  "ethics_ai_record_url": "https://ethics.ai/record/9523",
  "original_url": "https://doi.org/10.1016/s2468-1253(24)00034-7",
  "evidence_status": "source-only",
  "attribution": "via ethics.ai"
}